ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Catalent acquires Belgian cell therapy specialist

by Rick Mullin
February 8, 2020 | APPEARED IN VOLUME 98, ISSUE 6

 

The drug-services firm Catalent is buying MaSTherCell, a cell therapy manufacturing specialist based in Gosselies, Belgium, for $315 million. MaSTherCell operates a clinical-scale facility in Gosselies. A commercial-scale plant under construction will more than double the site’s staff of 240. MaSTherCell is also building a facility in Houston that will employ about 50 when it opens later this year. Catalent entered the adjacent gene therapy service market last year with its $1.2 billion acquisition of Paragon Bioservices.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment